Novel fluid biomarkers for mild cognitive impairment: A systematic review and meta-analysis
Ageing Research Reviews · 2023-11 · 91 · 102046
DOI: 10.1016/j.arr.2023.102046 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Ageing Research Reviews, 2023-11. Verfasst von Amish Gaur und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hurvitz Brain Sciences Program, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada; Department of Pharmacology & Toxicol…. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Alzheimer's Association.
Abstract (Originalsprache)
Mild cognitive impairment (MCI) is a well-established prodromal stage of dementia (e.g., Alzheimer's disease) that is often accompanied by early signs of neurodegeneration. To facilitate a better characterization of the underlying pathophysiology, we assessed the available literature to evaluate potential fluid biomarkers in MCI. Peer-reviewed articles that measured cerebrospinal fluid (CSF) and/or peripheral biomarkers of neuronal injury (total-tau [T-tau], neurofilament light chain [NfL], heart-type fatty acid binding protein [HFABP], neuron-specific enolase, ubiquitin C-terminal hydrolase L1) and/or astroglial pathology (glial fibrillary acidic protein [GFAP], S100 calcium-binding protein B) in MCI and healthy controls were assessed. Group differences were summarized by standardized mean differences (SMDs) and 95% confidence intervals calculated using a random-effects model. Heterogeneity was quantified using I2. A total of 107 studies were included in the meta-analysis and 10 studies were qualitatively reviewed. In CSF, concentrations of NfL (SMD = 0.69 [0.56, 0.83]), GFAP (SMD = 0.41 [0.07, 0.75]), and HFABP (SMD = 0.57 [0.26, 0.89]) were elevated in MCI. In blood, increased concentrations of T-tau (SMD = 0.19 [0.09, 0.29]), NfL (SMD = 0.41 [0.32, 0.49]), and GFAP (SMD = 0.39 [0.23, 0.55]) were found in MCI. Heterogeneity that was identified in all comparisons was explored using meta-regression and subgroup analysis. Elevated NfL and GFAP can be detected in both CSF and peripheral blood. Monitoring these biomarkers in clinical settings may provide important insight into underlying neurodegenerative processes in MCI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hurvitz Brain Sciences Program, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada; Department of Pharmacology & Toxicology, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1…
- Hurvitz Brain Sciences Program, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada.
- Hurvitz Brain Sciences Program, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada; Department of Psychiatry, University of Toronto, 250 College Street, 8th Floor, Toronto, ON M5T 1R8, Canad…
Förderung
- Canadian Institutes of Health Research
- Alzheimer's Association
Zitieren
APA
Gaur, A., Rivet, L., Mah, E., Bawa, K. K., Gallagher, D., Herrmann, N., & Lanctôt, K. L. (2023). Novel fluid biomarkers for mild cognitive impairment: A systematic review and meta-analysis. Ageing Research Reviews, 91, 102046. https://doi.org/10.1016/j.arr.2023.102046
Vancouver
Gaur A, Rivet L, Mah E, Bawa KK, Gallagher D, Herrmann N, et al. Novel fluid biomarkers for mild cognitive impairment: A systematic review and meta-analysis. Ageing Research Reviews. 2023;91:102046. doi:10.1016/j.arr.2023.102046
BibTeX
@article{Gaur2023,
author = {Gaur, Amish and Rivet, Luc and Mah, Ethan and Bawa, Kritleen K and Gallagher, Damien and Herrmann, Nathan and Lanctôt, Krista L},
title = {Novel fluid biomarkers for mild cognitive impairment: A systematic review and meta-analysis},
journal = {Ageing Research Reviews},
year = {2023},
volume = {91},
pages = {102046},
doi = {10.1016/j.arr.2023.102046}
}
EUVIMED